Date: March 1, 2016
A series of policy initiatives aimed at boosting the competitiveness and
production value of Taiwan’s biomedical and smart machinery industries were recently proposed by ROC President-elect Tsai Ing-wen.
The biomedical component includes reforms for 31 items covered under amendments to the Act for the Development of Biotech and New Pharmaceuticals Industry, Fundamental Science and Technology Act and Pharmaceutical Affairs Act. This raft of changes is prioritized for review in the ninth Legislature, which commenced sittings Feb. 19 in Taipei City.
“We hope these bills can be greenlighted by year-end,” Tsai said during a conference with industry leaders Feb. 23 at Nangang Software Park in Taipei City. “The biomedical industry in Taiwan is full of potential and what we need to do is boost production value by pooling the resources of the academic, public and private sectors.” [FULL STORY]